# A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）

> **NCT04453930** · PHASE2 · UNKNOWN · sponsor: **Peking Union Medical College Hospital** · enrollment: 60 (estimated)

## Conditions studied

- Small Cell Lung Carcinoma

## Interventions

- **DRUG:** Camrelizumab，an engineered anti-PD-1 antibody
- **DRUG:** Platinum
- **DRUG:** Irinotecan
- **DRUG:** Apatinib

## Key facts

- **NCT ID:** NCT04453930
- **Lead sponsor:** Peking Union Medical College Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-06-08
- **Primary completion:** 2023-06
- **Final completion:** 2023-06
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2020-07-01


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04453930

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04453930, "A Study of Sequential Therapy of Camrelizumab Combined With Chemotherapy（Irinotecan Plus Platinum）and With Apatinib in Participants With Untreated Advanced Small Cell Lung Cancer（SCLC）". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT04453930. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*